India, July 16 -- Emcure Pharmaceuticals and Sanofi India have entered into an exclusive distribution and promotion agreement for Sanofi's oral anti-diabetic (OAD) products in India, effective immediately.

Emcure will exclusively distribute and promote the company's OAD range of products that include well-established brands like Amaryl(R)and Cetapin(R).

While Sanofi will continue to own and manufacture these brands across its plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all of India.

Eric Mansion,General Manager Pharma Southeast Asia and India & MCO Lead, Sanofi said,"Over 100 millionIndians ar...